Thermo Fisher Scientific/$TMO
1D1W1MYTD1Y5YMAX
Capital at risk
About Thermo Fisher Scientific
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
- Ticker
- $TMO
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 125,000
- Headquarters
- Waltham, United States
- Website
- www.thermofisher.com
TMO Metrics
BasicAdvanced
$246B
35.80
$18.58
0.85
$1.80
0.28%
Price and volume
Market cap
$246B
Beta
0.85
52-week high
$671.47
52-week low
$435.27
Average daily volume
2M
Dividend rate
$1.80
Financial strength
Current ratio
1.551
Quick ratio
0.897
Long term debt to equity
0.742
Total debt to equity
0.806
Dividend payout ratio (TTM)
9.50%
Interest coverage (TTM)
6.00%
Profitability
EBITDA (TTM)
11,737
Gross margin (TTM)
40.91%
Net profit margin (TTM)
15.04%
Operating margin (TTM)
18.98%
Effective tax rate (TTM)
7.88%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
5.13%
Return on equity (TTM)
13.52%
Valuation
Price to earnings (TTM)
35.801
Price to revenue (TTM)
5.37
Price to book
4.67
Price to tangible book (TTM)
-11.85
Price to free cash flow (TTM)
34.001
Free cash flow yield (TTM)
2.94%
Free cash flow per share (TTM)
19.567
Dividend yield (TTM)
0.27%
Forward dividend yield
0.28%
Growth
Revenue change (TTM)
7.23%
Earnings per share change (TTM)
7.45%
3-year revenue growth (CAGR)
2.11%
10-year revenue growth (CAGR)
10.16%
3-year earnings per share growth (CAGR)
8.28%
10-year earnings per share growth (CAGR)
14.03%
3-year dividend per share growth (CAGR)
11.46%
10-year dividend per share growth (CAGR)
11.61%
What the Analysts think about TMO
Analyst ratings (Buy, Hold, Sell) for Thermo Fisher Scientific stock.
Analyst projections of the future price of Thermo Fisher Scientific stock.
Bulls say / Bears say
Thermo Fisher’s second-quarter revenue rose 10%, organic revenue rose 5%, adjusted EPS rose 13% and adjusted operating margin expanded to 22.8%. The company also raised its 2026 revenue forecast after stronger biotech and pharma spending and a recovery in laboratory instruments. (Thermo Fisher Scientific, Bloomberg)
Thermo Fisher says AI should improve drug discovery productivity and increase customer investment across its value chain. Management is targeting 7% long-term organic revenue growth and low-teens adjusted EPS growth, giving investors a clear operating-growth framework if execution holds. (Thermo Fisher Scientific)
India could become a meaningful growth market as biopharma research and manufacturing expand. Thermo Fisher is targeting 15%–20% customer-base growth there over the next five years, with additional demand expected from semiconductor and clean-energy investment. (Reuters)
Underlying growth was less impressive than the headline figure: second-quarter reported revenue grew 10%, but organic revenue grew only 5%. This means acquisitions, divestitures or currency contributed materially to reported growth and may not repeat. (Thermo Fisher Scientific)
The instrument recovery is promising but not yet proven durable. Analytical Instruments growth accelerated to 6.9% in the second quarter after being flat in the first, so a renewed slowdown in customer purchasing could quickly weaken the improvement. (Bloomberg)
Thermo Fisher remains exposed to customers’ capital-spending and government-funding decisions, as well as economic, political and exchange-rate conditions in its international operations. A squeeze on research budgets or a deterioration in overseas trading conditions could therefore pressure sales and margins. (Thermo Fisher Scientific)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
TMO Financial Performance
Revenues and expenses
TMO Earnings Performance
Company profitability
Upcoming events
TMO News
AllArticlesVideos
Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
Business Wire1 day ago
Thermo Fisher Sees Stronger Demand, Calls 2026 an ‘Outstanding Year'
MarketBeat1 week ago
Thermo Fisher, Wells Fargo, Nutrien And More On CNBC's ‘Final Trades'
Benzinga2 weeks ago
Funds containing TMO
AllEURGBPUSD
Fund name | Fund size | $TMO weighting |
|---|---|---|
iShares S&P 500 Health Care Sector€IUHE | €125M | 3.95% |
iShares AI Adopters and Applications€AIAA | €169M | 1.81% |
iShares AI Adopters and Applications£AIAA | £145M | 1.81% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 1.73% |
VanEck Morningstar Wide Moat€GMVM | €407M | 1.63% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.